Investigational drug · Phase 3
Tunlametinib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer Metastatic, Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
14
Any phase or sponsor naming "Tunlametinib"
First trial start
2023
Oct 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tunlametinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer Metastatic
- Melanoma
Approved drugs for the same conditions: Colorectal cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tunlametinib" as an intervention, largest first.
- MRD-positive AML Clinical StudyPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07131059 · 537 participants (planned) · Start May 11, 2024 · Primary completion May 10, 2028
Drug: Ivosidenib; Gilteritinib and 10 more · For: AML, Adult
Sites: Tianjin, China
- Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant MelanomaPivotal-lookingRecruiting
Shanghai Kechow Pharma, Inc.Industry
NCT06008106 · 165 participants (planned) · Start Nov 2, 2023 · Primary completion Sep 22, 2027
Drug: tunlametinib; paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin · For: Melanoma
Sites: Beijing, China
- Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerPivotal-lookingRecruiting
Shanghai Kechow Pharma, Inc.Industry
NCT06008119 · 165 participants (planned) · Start Oct 25, 2023 · Primary completion Dec 24, 2026
Drug: Tunlametinib plus Vemurafenib; Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab · For: Colorectal Cancer Metastatic
Sites: Beijing, China
Fudan UniversityAcademic, hospital or other
NCT07445022 · 110 participants (planned) · Start Jan 28, 2026 · Primary completion Sep 30, 2028
Drug: tunlametinib · For: Melanoma Advanced
Sites: Shanghai, China
Shanghai Juncell TherapeuticsIndustry
NCT06703398 · 98 participants (planned) · Start Dec 20, 2024 · Primary completion May 12, 2026
Drug: GC101 TIL; dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin · For: Melanoma
Sites: Beijing, China
- Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal CancerNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07714447 · 91 participants (planned) · Start Nov 30, 2026 · Primary completion Feb 1, 2029
Drug: Arm1; Arm 2 and 1 more · For: CRC (Colorectal Cancer); BRAF
Sites: Guangzhou, China
- Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal MalignanciesNot yet recruiting
Chinese PLA General HospitalAcademic, hospital or other
NCT07446270 · 90 participants (planned) · Start Mar 3, 2026 · Primary completion Oct 30, 2027
Drug: Colorectal cancer: Tunlametinib + cetuximab β; Pancreatic cancer: Tunlametinib + cetuximab β and 1 more · For: Treatment for Advanced Colorectal Cancer; Treatment for Advanced Pancreatic Cancer
- A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric CancerNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07507526 · 76 participants (planned) · Start Apr 2026 · Primary completion Apr 30, 2028
Drug: Tunlametinib+PD-1 mAb · For: Gastric Adenocarcinoma
Sites: Guangzhou, China
- Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07463677 · 55 participants (planned) · Start Mar 15, 2026 · Primary completion May 31, 2028
Drug: Tunlametinib + Cetuximab β; Tunlametinib + Fulzerasib · For: Lung Cancer (NSCLC)
Fudan UniversityAcademic, hospital or other
NCT06970353 · 40 participants (planned) · Start May 27, 2025 · Primary completion Dec 30, 2026
Drug: Tunlametinib; Tunlametinib+PD-1 mAb · For: Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation; Advanced PDTC or ATC With NRAS Mutation
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Tunlametinib Suppresses Melanogenesis Induces Cell Cycle Arrest and Apoptosis in Giant Congenital Melanocytic Nevus Cells.
Guan JY, Chen Z, Liu WS, et al. · Cancers (Basel) 2026
- Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research.
Wang Z, Huang J, Liu J, et al. · Clin Cancer Res 2026
- Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report.
Zhou S, Chen Y, Gao G, et al. · Anticancer Drugs 2026
- Melanoma: Pathogenesis and Targeted Therapy.
Fu Y, Liu J, Mo Z, et al. · MedComm (2020) 2026
- Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time-Of-Flight Mass Spectrometry.
Yang Y, Gao J, Zeng H · Rapid Commun Mass Spectrom 2025
- Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.
Wang Y, Xu G, Xia H · Br J Dermatol 2025
Also in development for Colorectal Cancer Metastatic
- EB-DUO-CAR-NK-CEAGCCPhase 22 trials
Beijing Biotech · Colorectal Cancer Metastatic, Adenocarcinoma of Colon, Colorectal Cancer
- HDM2017Phase 22 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · CRC, Colorectal Cancer, Colorectal Cancer Metastatic
- XNW27011ASP546CPhase 22 trials
Astellas · Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
- DKN-01LY2812176Phase 21 trial
Leap Therapeutics, Inc. · Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer
- ImofinostatABT-301, MPT0E028Phase 21 trial
Anbogen Therapeutics, Inc. · Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)
- TL938Phase 21 trial
Teligene US · Colorectal Cancer Metastatic, Advanced Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.